At the recent meeting in Hawaii of the American Academy of Neurology, we heard many positive comments about CNS Spectrums. We were also urged by the attending neurologists to try and include more articles and issues devoted to neurologic disease and mechanisms.
Previously, we have had issues on epilepsy and stroke, and future issues are planned that will cover movement disorders, multiple sclerosis, child neurology, and Alzheimer's disease. We very much want and welcome both suggestions for neurological topics to which future issues may be dedicated and submission of unsolicited original research and review articles dealing with neurological topics. Our peer review process is quick and efficient. Accepted articles will be scheduled to appear as rapidly as possible.
This issue, whose articles I will discuss out of the printed order, is devoted largely to a topic of interest to neurologists and psychiatrists alike-migraine. Four papers deal with various aspects of migraine headache, a common and often plaguing disorder that still mystifies scientists and often eludes response to therapy. It is not an easy condition to diagnose; unlike many neurologic disorders, but in common with most psychiatric illness, there are no definitive objective tests that can make a positive diagnosis of migraine headache. Rather, after ruling out other causes of headache, like brain tumor, the neurologist must rely largely on history. Sometimes, the elicitation of symptoms like an aura can be nearly pathognomonic, but more often migraine is a diagnosis of exclusion by history alone. Treatment relies on palliative measures, including a variety of analgesics, some of which have abuse potential, ergotamine, (3-blockers, anticonvulsants, and serotoninenhancing drugs. Antidepressants generally are not effective in treating migraine headache; in some patients they seem to help while in others they worsen the situation.
Adding to this complexity, as Nancy C.P. Low, MD, MS, and Kathleen Ries Merikangas, PhD, of the National Institute of Mental Health, is the fact that migraine is highly comorbid with a host of other medical problems. These involve almost all organ systems and include psychiatric illness. Unfortunately, this penchant for co-occurrence with other disorders has not shed much light on the fundamental pathophysiology of migraine headache, but it does sometimes obscure the diagnosis. Their article is important as a reminder to think about migraine in patients with headache even in the face of multiple other problems.
Two articles suggest possible new treatment approaches to migraine. Keith R. Edwards, MD, from the Neurological Research Center in Bennington, Vermont, and colleages, from various other locations, combine data from two single-site, double-blind, placebo-controlled trials of the anticonvulsant topiramate for migraine prophylaxis. Seventy patients were enrolled and the results were positive: overall, topiramate produced a lower 28-day migraine frequency than placebo. About five times as many patients responded to topiramate than to placebo, although the overall response rate to the active drug was low (35.3%). Topiramate-associated adverse events included paresthesia and memory impairment. As has been observed before, topiramate also caused appetite suppression and weight loss. As I am a consultant to the manufacturer of topiramate (and therefore did not participate in the review of this article), I will refrain here from making any conclusions except to say that future studies of topiramate will be of great interest. Nabih M. Ramadan, MD, from the Chicago Medical School argues convincingly in his paper that migraine headache may involve an abnormal activation of glutamatergic neuronal pathways and suggests that glutamate antagonists, which appear to work in animal models of migraine, might be useful therapeutically. This work provides both a mechanistic hypothesis and a suggestion for treatment approaches and deserves careful scrutiny by both investigators and clinicians.
By contrast to these positive notes about therapeutics, William B. Young, MD, and colleagues from the Thomas Jefferson University Hospital provide data from a study of 50 patients with severe headache, most of who had migraine, who were admitted to an outpatient infusion center. Seventeen of these patients also had restless legs syndrome and these individuals turned out to have a very high risk of developing akathisia following administration of intravenous dopamine receptor blocking agents. The authors suggest that increased surveillance for restless legs syndrome in headache patients might be important prior to initiating therapy with dopamine receptor antagonists.
A final paper in this issue deals with a completely separate topic, obsessive-compulsive disorder (OCD). Donatella Marazziti, MD, of the University of Pisa and an associate international editor of CNS Spectrums notes that about onethird of patients with OCD do not respond to serotonin reuptake inhibitor medications. Dr. Marazziti reports a positive experience with venlafaxine for such patients, a medication that blocks both serotonin and norepinephrine reuptake in a manner similar to clomipramine but with fewer adverse events. This is welcome news for clinicians and patients alike dealing with the often very hard to treat syndrome of OCD.
Finally, I want to remind our readers that CNS Spectrums is now accepting letters to the editor. 
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Pooled data from five 4-to 6-week, placebo-controlled clinical trials. *There is no statistical difference in the incidence of discontinuation due to adverse events, and the types of adverse events that led to discontinuation were similar between placebo-treated patients and patients treated with Abilify.
Treatment-emergent adverse events reported at an incidence >10% and greater than placebo include headache, anxiety, insomnia, nausea, vomiting, lightheadedness, somnolence, akathisia, and constipation.
As with all antipsychotic medications, a rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported. As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia (TD).
Abilify may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
As with other antipsychotic drugs, Abilify should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold. Seizures occurred in 0.1% of Abilify-treated patients in placebocontrolled trials. EPS* -6% vs placebo 6% Hyperprolactinemia 3 -1 . 8 % vs placebo 6.9%
QT C interval -No significant difference vs placebo * Patient-reported adverse events in 4-and 6-week placebo-controlled trials. t i n patients with prolactin levels less than or equal to the upper limit of normal at baseline.
In a 52-week study, the percentage of patients with >7% increase in body weight was 30% 
CONTRAINDICATIONS
ABILIFY is contraindicated in patients with a known hypersensitivity to the product.
WARNINGS Neuroleptic Malignant Syndrome (NMS):
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including aripiprazole. Two possible cases of NMS occurred during aripiprazole treatment in the premarketing worldwide clinical database. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS).
Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: 1} immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.
Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, ABILIFY should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY despite the presence of the syndrome.
PRECAUTIONS

General:
Orthostatic Hypotension: Aripiprazole may be associated with orthostatic hypotension, perhaps due to its ai-adrenergic receptor antagonism. The incidence of orthostatic hypotension associated events from five short-term, placebo-controlled trials in schizophrenia (n-926) on ABILIFY (aripiprazole) included: orthostatic hypotension (placebo 1%, aripiprazole 1.9%); orthostatic lightheadedness (placebo 1%, aripiprazole 0.9%), and syncope (placebo 1%, aripiprazole 0.6%). The incidence of a significant orthostatic change in blood pressure (defined as a decrease of at least 30 mmHg in systolic blood pressure when changing from a supine to standing position) for aripiprazole was not statistically different from placebo (14% among aripiprazole-treated patients and 12% among placebo-treated patients). Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizure: Seizures occurred in 0.1% (1/926) of aripiprazole-treated patients in short-term, placebo-controlled trials. As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Potential for Cognitive and Motor Impairment: In short-term, placebo-controlled trials, somnolence was reported in 11% of patients on ABILIFY compared to 8% of patients on placebo; somnolence led to discontinuation in 0.1% (1/926) of patients on ABILIFY in short-term, placebo-controlled trials. Despite the relatively modest increased incidence of somnolence compared to placebo, ABILIFY, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely. Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing aripiprazole for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. , and 87 years) died following the discontinuation of ABILIFY in the double-blind phase of the study (causes of death were pneumonia, heart failure, and shock). The fourth patient (age 78 years) died following hip surgery while in the double-blind portion of the study. The treatment-emergent adverse events that were reported at an incidence of >5% and having a greater incidence than placebo in this study were accidental injury, somnolence, and bronchitis. Eight percent of the ABILIFY-treated patients reported somnolence compared to one percent of placebo patients. In a small pilot, open-label, ascending-dose cohort study (n=30) in elderly patients with dementia, ABILIFY was associated in a dose-related fashion with somnolence. Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10-to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro (see CLINICAL PHARMACOLOGY: DrugDrug Interactions). Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY. Carcinogenesis, Mutagenesis, Impairment of Fertility: (Please see Full Prescribing Information). Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is not known whether aripiprazole can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aripiprazole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Labor and Delivery: The effect of aripiprazole on labor and delivery in humans is unknown. Nursing Mothers: Aripiprazole was excreted in milk of rats during lactation. It is not known whether aripiprazole or its metabolites are excreted in human milk. It is recommended that women receiving aripiprazole should not breast-feed. Pediatric Use: Safety and effectiveness in pediatric and adolescent patients have not been established. Geriatric Use: Of the 5592 patients treated with aripiprazole in premarketing clinical trials, 659 (12%) were >65 years old and 525 (9%) were >75 years old. The majority (91%) of the 659 patients were diagnosed with dementia of the Alzheimer's type. Placebo-controlled studies of aripiprazole in schizophrenia did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There was no effect of age on the pharmacokinetics of a single 15-mg dose of aripiprazole. Aripiprazole clearance was decreased by 20% in elderly subjects (>65 years) compared to younger adult subjects (18 to 64 years), but there was no detectable effect of age in the population pharmacokinetic analysis in schizophrenia patients. Studies of elderly patients with psychosis associated with Alzheimer's disease, have suggested that there may be a different toierabiiity profile in this population compared to younger patients with schizophrenia (see PRECAUTIONS: Use in Patients with Concomitant Illness). The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with Alzheimer's disease has not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised. Short-Term, Placebo-Controlled Trials:Treatment-emergent adverse events that occurred during acute therapy (up to 6 weeks) at an incidence of 2% or more of patients treated with aripiprazole (doses >2 mg/day) and for which the incidence was greater than the incidence reported for placebo were: Body as a Whole-headache, asthenia, and fever; Digestive Systemnausea, vomiting, and constipation; Nervous System -anxiety, insomnia, lightheadedness, somnolence, akathisia, and tremor; Respiratory System -rhinitis and coughing; Skin and Appendages -rash; Special Senses -blurred vision.
ADVERSE REACTIONS
Dose-Related Adverse Events:
The only adverse event to have a possible dose response relationship, and then most prominent only with 30 mg, was somnolence (placebo, 7.7%; 15-mg, 8.7%; 20-mg, 7.5%; 30-mg, 15.3%) . Extrapyramidal Symptoms: In short-term, placebo-controlled trials, the incidence of reported EPS for aripiprazole-treated patients was 6% vs. 6% for placebo. Objectively collected data from those trials on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales (for dyskinesias) also did not show a difference between aripiprazole and placebo, with the exception of the Barnes Akathisia Scale (aripiprazole, 0.08; placebo, -0.05 Nervous System: Frequent -depression, nervousness, increased salivation, hostility, suicidal thought, manic reaction, abnormal gait, confusion, cogwheel rigidity; Infrequent -dystonia, twitch, impaired concentration, paresthesia, vasodilation, hypesthesia, extremity tremor, impotence, bradykinesia, decreased libido, panic attack, apathy, dyskinesia, hypersomnia, vertigo, dysarthria, tardive dyskinesia, ataxia, impaired memory, stupor, increased libido, amnesia, cerebrovascular accident, hyperactivity, depersonalization, hypokinesia, restless leg, myoclonus, dysphoria, neuropathy, increased reflexes, slowed thinking, hyperkinesia, hyperesthesia, hypotonia, oculogyric crisis; Rare -delirium, euphoria, buccoglossal syndrome, akinesia, blunted affect, decreased consciousness, incoordination, cerebral ischemia, decreased reflexes, obsessive thought, intracranial hemorrhage. Respiratory System: Frequent -dyspnea, pneumonia; Infrequent-asthma, epistaxis, hiccup, laryngitis; Rare -hemoptysis, aspiration pneumonia, increased sputum, dry nasal passages, pulmonary edema, pulmonary embolism, hypoxia, respiratory failure, apnea. Skin and Appendages: Frequent -dry skin, pruritus, sweating, skin ulcer; Infrequentacne, vesiculobullous rash, eczema, alopecia, psoriasis, seborrhea; Raremaculopapular rash, exfoliative dermatitis, urticaria. Special Senses: ' Frequent-conjunctivitis, ear pain; Infrequent-dry eye, eye pain, tinnitus, otitis media, cataract, altered taste, blepharitis; Rare -increased lacrimation, frequent blinking, otitis externa, amblyopia, deafness, diplopia, eye hemorrhage, photophobia. Urogenital System: Frequent -urinary incontinence; Infrequentcystitis, urinary frequency, leukorrhea, urinary retention, hematuria, dysuria, amenorrhea, abnormal ejaculation, vaginal hemorrhage, vaginal moniliasis, kidney failure, uterus hemorrhage, menorrhagia, albuminuria, kidney calculus, nocturia, polyuria, urinary urgency; Rare -breast pain, cervicitis, female lactation, anorgasmy, urinary burning, glycosuria, gynecomastia, urolithiasis, priapism.
OVERDOSAGE
Management of Overdosage:
No specific information is available on the treatment of overdose with aripiprazole. An electrocardiogram should be obtained in case of overdosage and, if QTC interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers. Charcoal -In the event of an overdose of ABILIFY, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of aripiprazole, decreased the mean AUC and Cmax of aripiprazole by 50%.
